Providing comprehensive and timely information to our shareholders is important to us. The company has provided background information on our target diseases, the available clinical data, and our rationale for each Phase 3 study design, in the form of an investor webcast.
Cenerimod Phase 3 initiation
In December 2022, Idorsia announced that the first patient has entered screening to participate in OPUS, a Phase 3 program to investigate the efficacy and safety of cenerimod, Idorsia’s novel, highly selective S1P1 receptor modulator, as an oral treatment for adult patients with moderate to severe systemic lupus erythematosus.
Aprocitentan Phase 3 data published in The Lancet
In November 2022, Idorsia announced the publication of “A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension” in The Lancet.
Daridorexant Phase 3 data published in The Lancet Neurology
In January 2022, Idorsia announced the publication of "Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials" in The Lancet Neurology.
Selatogrel Phase 3 initiation
In June 2021, Idorsia announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).
The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.